Suggestions will update as you type

Want to connect with a local rep or request a demo pen?

Access Additional Start Resources

By providing my professional information, I agree that it may be used by Eli Lilly and Company ("Lilly") and its affiliates and partners or third parties, working on Lilly's behalf, for Lilly's marketing or promotional purposes. I may unsubscribe/opt-out by clicking the unsubscribe link within any email I receive or by calling 1-800-LILLYRX (1-800-545-5979). For more information about Lilly's privacy practices, please view the Privacy Statement.

Mounjaro 2.5 mg pen

How to Prescribe Mounjaro

Help get patients started on Mounjaro1

Mounjaro 2.5 mg pen

Start

Provide patients with a 1-month* 2.5 mg starting dose prescription

The 2.5-mg dose is for treatment initiation and is not intended for glycemic control.

Rx pad with text that says: Mounjaro 5 milligram pen per 0.5 milliliters. Inject 5 milligrams SC once weekly. 84-day supply dispense 6 milliliters.

Prescribe

After 4 weeks on the 2.5 mg dose, provide patients with a 1-month* or 3-month 5.0-mg prescription

Icon of clipboard with illustration of shield and cross in the middle

Access

See personalized formulary access and top plans

Learn More
Icon of savings card with text that says: Pay as little as $25 for a 1-month prescription with the Mounjaro Savings Program

Activate

Help your eligible patients save on Mounjaro

For eligible, commercially insured patients with Mounjaro coverage, Governmental beneficiaries excluded, terms and conditions apply

Prior authorizations are common for incretin therapies. Get tips for Prior Authorization Submission Process.

Download PA Guide

*One month is defined as 28 days and 4 pens.
†Three months is defined as 84 days and up to 12 pens.
See Savings Card Terms and Conditions 2.5-mg dose NDC: 0002-1506-80; 5-mg dose NDC: 0002-1495-80

How to Dose Mounjaro

Multiple doses for customizable glycemic control1‡

START THE EXPERIENCE

Mounjaro 2.5 milligram pen once weekly

Starting dose (for 4 weeks)

Month 1

CONTINUE THE EXPERIENCE

Mounjaro 5 milligram pen once weekly

For at least 4 weeks

Month 2

IF ADDITIONAL GLYCEMIC CONTROL IS NEEDED

Mounjaro 7.5 milligram pen once weekly

For at least 4 weeks

Mounjaro 10 milligram pen once weekly

For at least 4 weeks

Mounjaro 12.5 milligram pen once weekly

For at least 4 weeks

Mounjaro 15 milligram once weekly

Maximum dose

The 2.5-mg dose is for treatment initiation and is not intended for glycemic control.1
Consider patient history and monitor for tolerability and side effects.

Patient Start Resources

Tips and resources for you and your staff

Icon representing PA Form

Completing Prior Authorization

A helpful guide on how to complete a prior authorization.

Read Guide
Mounjaro Treatment Initiation video

Getting Started Video

A video guide on initiating treatment, dosing options and what to expect with side effects

Watch Video

Resources for your patients

Icon of Mounjaro Digital Starter Kit

Digital Starter Kit

Tell your patients to text MJ to 85099 to download a free kit to help them get started on Mounjaro.

The kit provides tips on starting Mounjaro, what to expect, reminder options and additional resources.

Icon of Mounjaro Digital Starter Kit

Download Patient Brochure

The brochure provides additional tips on starting Mounjaro, what to expect, reminder options and additional resources.

Download Now
ALL

Download Savings Card

Download a savings card for your eligible, commercially insured patients with Mounjaro coverage.*

*Governmental beneficiaries excluded, terms and conditions apply

Download Now
Lilly play icon

Discover Lilly Play

Watch videos about Mounjaro and how to help your patients get started.

Prescribing in your EHR System

Help patients get from initiation to a therapeutic dose of Mounjaro

Select Important Safety Information:

Risk of Thyroid C-cell Tumors: Counsel patients regarding the potential risk for MTC with the use of Mounjaro and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Mounjaro. Such monitoring may increase the risk of unnecessary procedures, due to the low test specificity for serum calcitonin and a high background incidence of thyroid disease. Significantly elevated serum calcitonin values may indicate MTC and patients with MTC usually have calcitonin values >50 ng/L. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated.

References:

  1. Mounjaro. Prescribing Information. Lilly USA, LLC.
Mounjaro wayfinder icon

Mounjaro (tirzepatide) is currently only available in a pre-filled single-dose pen manufactured by Lilly. Mounjaro is not commercially available in any other form (e.g., powder for compounding). Products claiming to be compounded Mounjaro (tirzepatide) are not subject to FDA approval and may not have the same safety, quality and efficacy as FDA-approved drugs, and may expose patients to potentially serious health risks.

INDICATION

Mounjaro (tirzepatide), an injectable prescription medicine, is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Limitations of Use: Mounjaro has not been studied in patients with a history of pancreatitis. Mounjaro is not indicated for use in patients with type 1 diabetes mellitus.

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF THYROID C-CELL TUMORS

In both male and female rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Mounjaro causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.

Mounjaro is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Mounjaro and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Mounjaro.

Mounjaro is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with known serious hypersensitivity to tirzepatide or any of the excipients in Mounjaro. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with Mounjaro.

Risk of Thyroid C-cell Tumors

Counsel patients regarding the potential risk for MTC with the use of Mounjaro and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Mounjaro. Such monitoring may increase the risk of unnecessary procedures, due to the low test specificity for serum calcitonin and a high background incidence of thyroid disease. Significantly elevated serum calcitonin values may indicate MTC and patients with MTC usually have calcitonin values >50 ng/L. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated.

Pancreatitis

Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists. Pancreatitis has been reported in Mounjaro clinical trials. Mounjaro has not been studied in patients with a prior history of pancreatitis. It is unknown if patients with a history of pancreatitis are at higher risk for development of pancreatitis on Mounjaro. Observe patients for signs and symptoms, including persistent severe abdominal pain sometimes radiating to the back, which may or may not be accompanied by vomiting. If pancreatitis is suspected, discontinue Mounjaro and initiate appropriate management.

Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin

Concomitant use with an insulin secretagogue (e.g., sulfonylurea) or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. The risk of hypoglycemia may be lowered by reducing the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.

Hypersensitivity Reactions

Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported in patients treated with Mounjaro. If hypersensitivity reactions occur, discontinue use of Mounjaro; treat promptly per standard of care, and monitor until signs and symptoms resolve. Do not use in patients with a previous serious hypersensitivity to Mounjaro. Use caution in patients with a history of angioedema or anaphylaxis with a GLP-1 receptor agonist because it is unknown if such patients will be predisposed to these reactions with Mounjaro.

Acute Kidney Injury

Mounjaro has been associated with gastrointestinal adverse reactions, which include nausea, vomiting, and diarrhea. These events may lead to dehydration, which if severe could cause acute kidney injury. In patients treated with GLP-1 receptor agonists, there have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, sometimes requiring hemodialysis. Some of these events have been reported in patients without known underlying renal disease. A majority of reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration. Monitor renal function when initiating or escalating doses of Mounjaro in patients with renal impairment reporting severe adverse gastrointestinal reactions.

Severe Gastrointestinal Disease

Use of Mounjaro has been associated with gastrointestinal adverse reactions, sometimes severe. Mounjaro has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and is therefore not recommended in these patients.

Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy

Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Mounjaro has not been studied in patients with non-proliferative diabetic retinopathy requiring acute therapy, proliferative diabetic retinopathy, or diabetic macular edema. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.

Acute Gallbladder Disease

In clinical trials, acute gallbladder disease was reported by 0.6% of Mounjaro-treated patients and 0% of placebo-treated patients. If cholelithiasis is suspected, gallbladder diagnostic studies and appropriate clinical follow-up are indicated.

Most Common Adverse Reactions

The most common adverse reactions reported in ≥5% of Mounjaro treated patients in placebo controlled trials were nausea diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain.

Drug Interactions

When initiating Mounjaro, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia. Mounjaro delays gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications, so caution should be exercised.

Pregnancy

Limited data on Mounjaro use in pregnant women are available to inform on drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Based on animal reproduction studies, there may be risks to the fetus from exposure to tirzepatide. Use only if potential benefit justifies the potential risk to the fetus.

Lactation

There are no data on the presence of tirzepatide in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Mounjaro and any potential adverse effects on the breastfed infant from Mounjaro or from the underlying maternal condition.

Females of Reproductive Potential

Advise females using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation.

Pediatric Use

Safety and effectiveness of Mounjaro have not been established and use is not recommended in patients less than 18 years of age.

Please click to access Prescribing Information, including Boxed Warning about possible thyroid tumors, including thyroid cancer, and Medication Guide.

Please see Instructions for Use included with the pen.

TR HCP ISI 23MAY2023